Goldman Sachs’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$29.8M Buy
475,000
+421,000
+780% +$33.7M ﹤0.01% 2070
2025
Q4
$5.15M Sell
54,000
-370,000
-87% -$36.3M ﹤0.01% 3716
2025
Q3
$41.4M Buy
424,000
+370,000
+685% +$38.3M 0.01% 1580
2025
Q2
$5.8M Hold
54,000
﹤0.01% 3278
2025
Q1
$5.45M Hold
54,000
﹤0.01% 3266
2024
Q4
$4.82M Hold
54,000
﹤0.01% 3495
2024
Q3
$4.53M Buy
+54,000
New +$4.26M ﹤0.01% 3432
2024
Q2
Sell
-140,000
Closed -$9.59M 5666
2024
Q1
$9.59M Sell
140,000
-12,900
-8% -$829K ﹤0.01% 2487
2023
Q4
$8.84M Sell
152,900
-77,100
-34% -$4.12M ﹤0.01% 2648
2023
Q3
$12.1M Buy
230,000
+67,600
+42% +$3.55M ﹤0.01% 2223
2023
Q2
$8.78M Buy
+162,400
New +$8.48M ﹤0.01% 2576
2022
Q4
Sell
-21,600
Closed -$837K 5992
2022
Q3
$837K Sell
21,600
-8,600
-28% -$345K ﹤0.01% 4631
2022
Q2
$1.13M Sell
30,200
-13,200
-30% -$537K ﹤0.01% 4521
2022
Q1
$1.92M Sell
43,400
-59,300
-58% -$2.57M ﹤0.01% 4298
2021
Q4
$4.36M Buy
102,700
+42,700
+71% +$1.79M ﹤0.01% 3545
2021
Q3
$2.6M Hold
60,000
﹤0.01% 3946
2021
Q2
$2.57M Buy
60,000
+34,700
+137% +$1.46M ﹤0.01% 3972
2021
Q1
$978K Sell
25,300
-99,300
-80% -$3.76M ﹤0.01% 4632
2020
Q4
$4.48M Hold
124,600
﹤0.01% 3085
2020
Q3
$4.76M Sell
124,600
-76,800
-38% -$2.96M ﹤0.01% 2945
2020
Q2
$7.07M Buy
201,400
+168,300
+508% +$6.06M ﹤0.01% 2526
2020
Q1
$1.08M Buy
33,100
+6,200
+23% +$242K ﹤0.01% 3696
2019
Q4
$1.22M Sell
26,900
-38,200
-59% -$1.6M ﹤0.01% 3999
2019
Q3
$2.65M Buy
65,100
+4,800
+8% +$203K ﹤0.01% 3342
2019
Q2
$2.59M Sell
60,300
-46,400
-43% -$1.78M ﹤0.01% 3364
2019
Q1
$4.09M Sell
106,700
-40,300
-27% -$1.54M ﹤0.01% 3141
2018
Q4
$5.2M Buy
147,000
+145,400
+9,088% +$5.27M ﹤0.01% 2845
2018
Q3
$62K Hold
1,600
﹤0.01% 5250
2018
Q2
$52K Hold
1,600
﹤0.01% 5347
2018
Q1
$44K Sell
1,600
-22,800
-93% -$620K ﹤0.01% 5502
2017
Q4
$605K Buy
24,400
+3,200
+15% +$88.3K ﹤0.01% 4680
2017
Q3
$618K Buy
21,200
+2,700
+15% +$74.6K ﹤0.01% 4948
2017
Q2
$513K Sell
18,500
-6,000
-24% -$159K ﹤0.01% 5072
2017
Q1
$609K Sell
24,500
-200,100
-89% -$4.87M ﹤0.01% 4833
2016
Q4
$4.86M Buy
224,600
+100,100
+80% +$2.18M ﹤0.01% 3078
2016
Q3
$2.96M Buy
124,500
+300
+0.2% +$7.16K ﹤0.01% 3488
2016
Q2
$2.9M Buy
124,200
+48,400
+64% +$1.05M ﹤0.01% 3299
2016
Q1
$1.43M Sell
75,800
-12,200
-14% -$214K ﹤0.01% 3775
2015
Q4
$1.62M Sell
88,000
-135,800
-61% -$2.43M ﹤0.01% 3820
2015
Q3
$3.67M Sell
223,800
-142,000
-39% -$2.43M ﹤0.01% 3172
2015
Q2
$6.47M Buy
365,800
+133,000
+57% +$2.38M ﹤0.01% 2716
2015
Q1
$4.13M Sell
232,800
-372,600
-62% -$5.89M ﹤0.01% 3086
2014
Q4
$8.02M Buy
605,400
+168,500
+39% +$2.15M ﹤0.01% 2532
2014
Q3
$5.16M Sell
436,900
-102,900
-19% -$1.3M ﹤0.01% 2981
2014
Q2
$6.89M Sell
539,800
-1,616,900
-75% -$21M ﹤0.01% 2705
2014
Q1
$29.2M Sell
2,156,700
-4,865,400
-69% -$63.9M 0.01% 1463
2013
Q4
$84.4M Buy
7,022,100
+5,101,300
+266% +$60.3M 0.03% 710
2013
Q3
$22.6M Buy
1,920,800
+282,100
+17% +$3.05M 0.01% 1529
2013
Q2
$15.2M Buy
+1,638,700
New +$13.9M 0.01% 1730

Other funds holding BSX

Goldman Sachs's BSX Position: Q1 2026 in Review

Goldman Sachs increased its Boston Scientific (BSX) stake by 14% in Q1 2026, buying an estimated $185M and bringing the position to 18,891,624 shares worth $1.19B. The position accounts for 0.14% of the portfolio, ranked #133.

Goldman Sachs first reported a position in BSX in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.58B in Q4 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Goldman Sachs held 18,891,624 shares of Boston Scientific worth $1.19B as of Q1 2026.
  • Goldman Sachs bought 2,312,707 Boston Scientific shares in Q1 2026, an estimated $185M.
  • Boston Scientific made up 0.14% of Goldman Sachs's portfolio in Q1 2026, its #133 holding.
  • Goldman Sachs first reported a position in Boston Scientific in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Boston Scientific position peaked at $1.58B in Q4 2025.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.